Tofacitinib vs methotrexate for severe alopecia areata
Treatments studied
Part of Skin clinical trials.
This trial compares two medications, tofacitinib and methotrexate, to see which works better for severe hair loss caused by alopecia areata. If you have severe alopecia areata (total or universal hair loss), this study may offer a chance to try a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed with severe alopecia areata, alopecia totalis, or alopecia universalis.
- You have not used any systemic treatments (like steroids or JAK inhibitors) for hair regrowth in the recent past.
- You are not pregnant.
- You do not have a history of kidney, liver, or lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medicines, cyclosporine and methotrexate, to see which works better for children with alopecia areata (a condition causing hair loss). It aims to help doctors choose the best treatment for each child.
This study tests if a cream containing methotrexate (a medicine that affects the immune system) can help regrow hair in people with mild alopecia areata (patchy hair loss on the scalp). It compares the methotrexate cream to a standard treatment cream (minoxidil) to see which works better.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
This study looks at how well JAK inhibitor pills work for children with alopecia areata (a condition that causes hair loss). If you have tried one of these medicines for at least 3 months, your experience could help doctors learn more about the best treatments.
This study tests a pill called baricitinib for people with active alopecia areata that started within the last 3 months. Baricitinib is a type of medication called a JAK inhibitor, which can help calm the immune system and stop hair loss.
This trial tests an oral medication called NXC-736 for people with moderate to severe alopecia areata. It aims to see if the drug is safe and can help regrow hair.
Hear when a new Alopecia Areata trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.